GotoPER - Physicians' Education Resource
Back to Home
Free CE/CMEVideo

Show Me the Data™: Redefining Treatment Paradigms in Triple-Negative Breast Cancer Across the Disease Continuum

Create AccountAlready Registered? Login Here

Release Date

June 5, 2026

Expiration Date

July 1, 2026

Credits

1.5 CME, NCPD

Specialties

Breast Cancer, Medical Oncology+1 more

Activity Overview

This educational activity is an archive of the live presentation held on May 29, 2026.

For more information about this educational activity, the faculty, and disclosures, please click here.

Target Audience

This educational activity is directed toward medical oncologists, surgical oncologists, advanced practice professionals, pathologists, oncology nurses, and other health care practitioners who manage patients with breast cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Evaluate emerging evidence from pivotal trials to determine their impact on evolving treatment paradigms in early-stage and metastatic triple-negative breast cancer (TNBC)
  • Incorporate biomarker testing alongside patient-specific factors into personalized treatment plans for patients with TNBC
  • Identify key differences in the safety profiles of PARP inhibitors, immunotherapies, and antibody-drug conjugates (ADCs) used for the treatment of TNBC
  • Assess unique targets, structures, and mechanisms of novel therapies under investigation for the treatment of TNBC
    Show Me the Data™: Redefining Treatment Paradigms in Triple-Negative Breast Cancer Across the Disease Continuum

    GET STARTED WITH THIS PROGRAM:

    Register now to gain access to this program.

    Create AccountAlready Registered? Login Here

    Accreditation/Credit Designation

    Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.50 Contact Hours.

    Acknowledgment of Commercial Support

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals; BioNTech; Daiichi Sankyo, Inc; and Merck Sharp & Dohme LLC.

    Follow Us on Social Media!

    Related Content

    Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Wisconsin Association of Hematology and OncologyFree CE/CME

    Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Wisconsin Association of Hematology and Oncology

    Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Missouri Oncology SocietyFree CE/CME

    Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Missouri Oncology Society

    Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Nevada Oncology SocietyFree CE/CME

    Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Nevada Oncology Society

    Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | The Arizona Clinical Oncology SocietyFree CE/CME

    Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | The Arizona Clinical Oncology Society

    Course

    Show Me the Data™: Redefining Treatment Paradigms in Triple-Negative Breast Cancer Across the Disease Continuum

    Create Account